ECTRIMS 2023 - Lapucci Caterina
ECTRIMS 2023 - Lapucci Caterina
(478.1 KB)
A real-life, multicenter, observational study to evaluate safety and efficacy of the switch from alemtuzumab to ocrelizumab in MS patients with evidence of disease activity/progression after two alemtuzumab courses: the Italian experience
Lapucci C.1, Frau J.2, Cocco E.2, Coghe G.2, Petracca M3,4, Lanzillo R.3, Vercellino M.5, Cavalla P.5, Bianco A.6, Mirabella M.6, Di Mauro G.7, Landi D.7, Marfia G.7, Torri Clerici V.8, Tomas E.8, Ferrò M.T.9,
Grossi P.9, Zaffaroni M.10, Ronzoni M.11, Nozzolillo A.12, Moiola L.12, Pinardi F.13, Novi G.1, Cellerino M.14, Uccelli A.1,14, Inglese M1,14
ECTRIMS 2023 - Cellerino Maria
ECTRIMS 2023 - Cellerino Maria
(707.57 KB)
Impact of autologous hematopoietic stem cell transplantation on retinal atrophy in multiple sclerosis
Maria Cellerino1, Giacomo Boffa1,2, Tommaso Sirito1, Vincenzo Daniele Boccia1
ECTRIMS 2023 - Cellerino Maria
ECTRIMS 2023 - Cellerino Maria
(485.27 KB)
The effect of cladribine and fingolimod treatments on retinal atrophy: preliminary findings
Maria Cellerino*1, Tommaso Sirito1, Valentina Maneschi1, Vincenzo Daniele Boccia1, Alice
ECTRIMS 2023 - Boccia Daniele
ECTRIMS 2023 - Boccia Daniele
(550.62 KB)
Paramagnetic Rim Lesions Frequency in Pediatric and Adult
Multiple Sclerosis Patients with Similar Disease Duration
Vincenzo Daniele BOCCIA1, Maria CELLERINO1, Caterina LAPUCCI1, 2 Laura FALCITANO 3, Maria Margherita MANCARDI4, Mauro COSTAGLI1, 5, Giacomo BOFFA1, Matilde INGLESE1
